Select a Region
North America

Browsing Archive: CardiovascularCardiovascular | EVERSANA

EVERSANA
Posted on May 8, 20255/8/25

A U.S. payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease

Posted on November 4, 202411/4/24

Cardiovascular Disease State Assessment with EVERSANA Management Consulting

EVERSANA
Posted on September 25, 20239/25/23

Challenges and Burdens in the Coronary Artery Disease Care Pathway for Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Narrative Review.

EVERSANA
Posted on September 20, 20239/20/23

An improved definition and SAFE Rule for Predicting Difficult Intravascular Access (DIVA) in Hospitalized Adults

EVERSANA
Posted on February 1, 20232/1/23

Procedure cost-comparison analysis of liquid embolic system techniques using EVOH and n-BCA in the embolization of brain arteriovenous malformations

EVERSANA
Posted on February 1, 20232/1/23

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy

EVERSANA
Posted on January 2, 20231/2/23

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy

EVERSANA
Posted on October 2, 202010/2/20

“Long-Term Economic Impact of First Pass Effect (FPE) in Endovascular Stroke Treatment with the EMBOTRAP™ Device from the ARISE-II Study: An Asia-Pacific Economic Analysis”

EVERSANA
Posted on October 2, 202010/2/20

ECONOMIC IMPACT OF FIRST PASS EFFECT (FPE) IN ENDOVASCULAR STROKE TREATMENT WITH THE EMBOTRAP II DEVICE FROM THE ARISE II STUDY – ANNUAL HEALTHCARE RESOURCE USE ECONOMIC ANALYSIS FROM A EUROPEAN PERSPECTIVE

EVERSANA
Posted on October 2, 202010/2/20

Health economic impact of first-pass success among patients with acute ischemic stroke treated with mechanical thrombectomy: a United States and European perspective.

Cardiovascular